AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 192 min read$MANE

Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment

Veradermics (MANE) shares rose 10% after its oral hair-loss pill, VDPHL01, met all primary and secondary goals in a second Phase 3 trial. The pill increased hair count significantly compared to placebo with no serious cardiac events. The company expects 12-month safety data later this year. Veradermics has sufficient cash to potentially reach a launch, according to management.

Original reporting
finance.yahoo.com
Published Oct 19, 2026, 5:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 5:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MANEBullishHigh
01

Why it matters

Phase 3 success reduces regulatory risk and opens a large U.S. market, prompting a 10% intraday rally.

02

Market read

The trial data constitute a primary catalyst for the stock, likely driving short‑term buying pressure.

03

What to watch

Pricing versus cheap generic minoxidil and reimbursement risk may limit upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Veradermics (MANE) is a recently listed biotech focused on an oral minoxidil formulation for male pattern hair loss.

Company-level read

Ticker impact

$MANEBullishHigh confidence
Context

Veradermics reported positive Phase 3 results for its oral hair‑loss pill, driving a 10% share jump.

Expected impact

upward pressure as investors price in potential approval and market opportunity.

Evidence & confidence

Phase 3 success is a material catalyst for a biotech; the stock already rose 10% on the news, indicating strong market reaction.

Market effects

Sector

Strengthens the hair‑loss treatment niche and may boost peer biotech valuations.

Regional

U.S. biotech sector sees modest uplift.

Global

Limited to biotech investors; no broad market impact.

Counterpoint

What could challenge this read

If the upcoming 12‑month safety data reveal issues, the rally could reverse.

Key entities

  • Executive
    Reid Waldman, M.D.

    CEO of Veradermics, quoted on trial results.

Read at source← All news

StoryVeradermics reports Phase 3 trial success for oral hair‑loss drug VDPHL01

Related articles

OCT 19
MedAI 9/10

Veradermics’ stock up on male hair loss trial success

Veradermics' stock rose 6% after its Phase III trial for male hair loss drug VDPHL01 met all endpoints, showing significant hair growth vs. placebo. The drug was well-tolerated, with 78.8% and 85.0% of patients reporting improvement in once-daily and twice-daily arms, respectively. Veradermics aims for FDA approval, potentially becoming the first oral pill for pattern hair loss in 30 years.

finance.yahoo.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results

Veradermics (NYSE:MANE) reported positive results from its Phase III trial for VDPHL01 in male pattern hair loss, meeting all endpoints. The trial showed strong growth with mild to moderate adverse events. The company plans to release extension data from Study 302 later this year and expects results from a female pattern hair loss study in 2027. Veradermics has $820 million in cash and is evaluating regulatory filing strategies.

finance.yahoo.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics Stock Rises 7% After Positive Phase 3 Hair Loss Trial Results

Veradermics (MANE) stock rose 6.98% to $116.42 after positive Phase 3 trial results for its hair loss treatment VDPHL01, meeting all endpoints with statistical significance. The trial involved 536 males with mild-to-moderate hair loss, showing significant hair count increases compared to placebo. The company expects further data later this year and in 2027.

rttnews.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics posts positive Phase 3 '304' topline: VDPHL01 raises hair count up to 36.4 hairs/cm², no treatment‑related SAEs

Veradermics (MANE) reported positive Phase 3 results for VDPHL01, showing significant hair growth and a favorable safety profile. The study met all endpoints, with hair count increases of 28.6 (QD) and 36.4 (BID) hairs/cm² vs. 6.6 for placebo. Patient-reported improvements were 78.8% (QD) and 85.0% (BID) vs. 35.3% for placebo. No treatment-related serious adverse events were reported.

tradingview.com1 min
OCT 19
$MANEHighAI 8/10

Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss

Veradermics, Inc (MANE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with h

SEC EDGAR 8-K2 min